4 March 2011
Targeting specific proteins that play a part in prostate cancer growth could cut the number of deaths associated with the condition.
A new study conducted by Scott Tomlins, from the University of Michigan Medical School in the US, has shown that drugs which affect the SPINK1 protein actually have the capacity to shrink prostate cancer tumours.
In a mouse model, the drug was found to reverse prostate cancer growth in 74 per cent of cases.
Commenting on the research, which could lead to a new line of defence against prostate cancer, Mr Tomlins said: "The paradigm of cancer treatment is sort of shifting.
"Instead of treating all patients blindly, it's really looking at... the specific molecular alterations that that patients' cancer has."
The research, published on Tuesday (March 2nd) in the journal Science Transnational Medicine, also showed that the SPINK1 protein could be one of the factors affecting the spread of cancer.
1 Tomlins, Scott et al. "Therapeutic Targeting of SPINK1-Positive Prostate Cancer". Science Translational Medicine. Tuesday, March 2nd 2011.
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.